Cardium Therapeutics
5
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
1 terminated/withdrawn out of 5 trials
66.7%
-19.8% vs industry average
40%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease
Role: lead
Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization
Role: lead
Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)
Role: lead
Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities
Role: collaborator
Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina
Role: lead
All 5 trials loaded